2. Anti-infection
  3. Bacterial
  4. Obiltoxaximab

Obiltoxaximab  (Synonyms: ETI 204)

Cat. No.: HY-P9932

Molarity Calculator

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia.

For research use only. We do not sell to patients.

CAS No. : 1351337-07-9

Size Price Stock Quantity
1 mg USD 250 In-stock
5 mg USD 700 In-stock
10 mg USD 1120 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Obiltoxaximab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia[1][2][3][4].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Chimeric
In Vivo

Obiltoxaximab (16 mg/kg, i.v., a single dose for 70 days) for simulated populations of healthy and infected humans is comparable in overall serum exposures in individual infected macaques following obiltoxaximab, similar results in rabbit experiments[1].
Obiltoxaximab (16 mg/kg, i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores) leads to 100% survival challenged with B. anthracis spores in cynomolgus macaques and prevents systemic bacteremia in the vast majority of animals[2].
Obiltoxaximab (4 and 8 mg/kg, i.v. and i.m., a single dose for 9 h) postexposure prophylaxis (PEP) leads to 100% survival with the combination of Levofloxacin (HY-B0330) challenged with B. anthracis spores in rabbits[2].
Obiltoxaximab (8 mg/kg, i.v., a single dose, 29 days) combined with antibiotics or Doxycycline (HY-N0565) lowers bacteremia levels in protective antigen (PA) of anthrax induced rabbits[5].

Pharmacokinetics of intramuscular Obiltoxaximab[2]

Study and dose (mg/kg) Postchallenge dosing schedule Cmax (μg/mL) Tmax (days) AUC0-∞ (μg·day/mL) T1/2 (days) CL /F(mL/day/kg) Vz/F (mL/kg)
PEP 2
8 18 h 80.8 1.0 1030 7.50 7.76 84.0
8 24 h 86.5 1.0 788 5.20 10.2 76.2
16 18 h 165 1.0 2120 8.44 7.54 91.9
16 24 h 119 1.0 1990 9.85 8.03 114
PEP 3
16 24 h 142 1.0 2190 10.4 7.00 110
16 36 h 132 0.50 1540 7.09 10.0 106
16 48 h 104 3.0 2040 12.6 8.00 143

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human, macaques and rabbits[1]
Dosage: 16 mg/kg
Administration: i.v., a single dose, 70 days
Result: Overall serum exposures were comparable following obiltoxaximab in human, macaques and rabbits.
Animal Model: Cynomolgus macaques[2]
Dosage: 16 mg/kg
Administration: i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores
Result: Resulted in transient low levels of bacteremia in several animals, resolving in all animals after day 4, and the majority of animals remained abacteremic until day 56.
Animal Model: Rabbits[2]
Dosage: 4 and 8 mg/kg
Administration: i.v. and i.m. at 4 and 8 mg/kg, a single dose, 9 h
Result: Effectiveness in the PEP setting was initially examined in rabbits.
Animal Model: Protective antigen (PA) of anthrax induced rabbits[5]
Dosage: 8 mg/kg
Administration: i.v., a single dose, 29 days
Result: Lowered bacteremia levels between days 1 and 2 combined with antibiotics, eliminated bacteremia levels combined with Doxycycline (HY-N0565) in protective antigen (PA) of anthrax induced rabbits.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Obiltoxaximab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Obiltoxaximab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Obiltoxaximab1351337-07-9ETI 204ETI204ETI-204Bacterialanti-protective antigenimmunogenicityanthrax toxin assemblycell intoxicationinhalational anthraxbacteremiatoxemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Obiltoxaximab
Cat. No.:
HY-P9932
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.